Pricing Log in Create free account

Genmab A/S Sponsored ADR (GMAB) vs Revolution Medicines, Inc. (RVMD)

Genmab A/S Sponsored ADR and Revolution Medicines, Inc. are both Biotechnology companies. Revolution Medicines, Inc. is the larger, with a market value of $40.6B against $22.6B — 1.8× the size. Revolution Medicines, Inc. has negative trailing earnings, so its P/E is not meaningful; Genmab A/S Sponsored ADR trades at 29.1×. Genmab A/S Sponsored ADR grew revenue faster over the last twelve months: 22.3% against −8.81%. Genmab A/S Sponsored ADR has the higher net margin (19.1% vs 0.00%) and the higher return on invested capital (6.99% vs 0.00%). Across the 19 metrics below, Genmab A/S Sponsored ADR leads on 14 and Revolution Medicines, Inc. on 5.

Valuation

Metric GMAB RVMD Biotechnology median
P/E 29.13 n/m 8.50
P/S 5.49 1,394.67 9.71
P/B 3.81 14.40 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 22.58 n/m 0.64
EV/Sales 6.37 1,286.83 9.21
Earnings yield 3.43% (4.96%) (33.15%)
Free cash flow yield (27.97%) (3.28%) (25.50%)

Profitability

Metric GMAB RVMD Biotechnology median
Gross margin 93.03% 35.06% 65.16%
Operating margin 25.95% 0.00% 0.00%
Net margin 19.08% 0.00% 0.00%
Free cash flow margin (153.64%) 0.00% 0.00%
Return on equity 14.00% (79.09%) (56.36%)
Return on assets 8.30% (52.37%) (48.04%)
Return on invested capital 6.99% 0.00% 0.00%

Growth

Metric GMAB RVMD Biotechnology median
Revenue growth (TTM) 22.26% (8.81%) 6.02%
EPS growth (last fiscal year) (12.50%) (66.20%) 30.26%
Revenue growth, 5-year CAGR 19.15% (10.50%) 9.41%
Net income growth, 5-year CAGR 5.73% 0.00% 0.00%

Health

Metric GMAB RVMD Biotechnology median
Debt to equity 0.86 0.40 0.00
Current ratio 2.46 11.38 4.72
Net debt to EBITDA 3.13 1.47 0.96

Dividend

Metric GMAB RVMD Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric GMAB RVMD Biotechnology median
Market cap 22.60b 40.57b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack